Desq Long
Sign in

Company

Acrivon Therapeutics, Inc.

ACRV · CIK 0001781174

SEC FORM 4
$0.00

Acrivon Therapeutics, Inc. (ACRV)

Acquisition (code A) of 30,000 shares at $0 per share.

Reporting Person Levin Michaela · Officer Title Chief Business Officer · Transaction Code A

Traded Aug 31, 2026 · Disclosed Sep 2, 2026

Source: SEC Form 4 · 0000905148-26-004065 · filed 2026-09-02 · View filing →

SEC FORM 4
$30,969.03

Acrivon Therapeutics, Inc. (ACRV)

Sale of 14,036 shares at $2.2064 per share.

Reporting Persons Blume-Jensen Peter · Masson Kristina · Officer Title President and CEO · Transaction Code S

Traded Aug 25, 2026 · Disclosed Aug 27, 2026

Source: SEC Form 4 · 0000905148-26-003968 · filed 2026-08-27 · View filing →

SEC FORM 4
$2,470.29

Acrivon Therapeutics, Inc. (ACRV)

Sale of 1,229 shares at $2.01 per share.

Reporting Persons Blume-Jensen Peter · Masson Kristina · Officer Title President and CEO · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003836 · filed 2026-08-20 · View filing →

SEC FORM 4
$972.84

Acrivon Therapeutics, Inc. (ACRV)

Sale of 484 shares at $2.01 per share.

Reporting Persons Blume-Jensen Peter · Masson Kristina · Officer Title President and CEO · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003836 · filed 2026-08-20 · View filing →

SEC FORM 4
$1,214.04

Acrivon Therapeutics, Inc. (ACRV)

Sale of 604 shares at $2.01 per share.

Reporting Person Devroe Eric · Officer Title Chief Operating Officer · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003837 · filed 2026-08-20 · View filing →

SEC FORM 4
$804.00

Acrivon Therapeutics, Inc. (ACRV)

Sale of 400 shares at $2.01 per share.

Reporting Person Gamelin Erick · Officer Title Chief Development Officer · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003838 · filed 2026-08-20 · View filing →

SEC FORM 4
$371.85

Acrivon Therapeutics, Inc. (ACRV)

Sale of 185 shares at $2.01 per share.

Reporting Person Miller Mary · Officer Title Chief Legal Officer · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003839 · filed 2026-08-20 · View filing →

SEC FORM 4
$203.01

Acrivon Therapeutics, Inc. (ACRV)

Sale of 101 shares at $2.01 per share.

Reporting Person Peterson Katharine · Officer Title Chief Accounting Officer · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 20, 2026

Source: SEC Form 4 · 0000905148-26-003840 · filed 2026-08-20 · View filing →